- Home
- HOV vs ELVN Comparison
HOV vs ELVN Comparison
Compare HOV & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOV
- ELVN
- Stock Information
- Founded
- HOV 1959
- ELVN 2016
- Country
- HOV United States
- ELVN United States
- Employees
- HOV N/A
- ELVN N/A
- Industry
- HOV Homebuilding
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- HOV Consumer Discretionary
- ELVN Health Care
- Exchange
- HOV Nasdaq
- ELVN Nasdaq
- Market Cap
- HOV 843.6M
- ELVN 927.8M
- IPO Year
- HOV N/A
- ELVN 2020
- Fundamental
- Price
- HOV $90.03
- ELVN $17.77
- Analyst Decision
- HOV Sell
- ELVN Strong Buy
- Analyst Count
- HOV 2
- ELVN 4
- Target Price
- HOV $155.00
- ELVN $37.25
- AVG Volume (30 Days)
- HOV 67.9K
- ELVN 361.5K
- Earning Date
- HOV 05-20-2025
- ELVN 05-14-2025
- Dividend Yield
- HOV N/A
- ELVN N/A
- EPS Growth
- HOV N/A
- ELVN N/A
- EPS
- HOV 28.18
- ELVN N/A
- Revenue
- HOV $3,062,436,000.00
- ELVN N/A
- Revenue This Year
- HOV N/A
- ELVN N/A
- Revenue Next Year
- HOV $5.54
- ELVN N/A
- P/E Ratio
- HOV $3.20
- ELVN N/A
- Revenue Growth
- HOV 7.85
- ELVN N/A
- 52 Week Low
- HOV $81.15
- ELVN $13.30
- 52 Week High
- HOV $240.34
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- HOV 41.57
- ELVN 49.54
- Support Level
- HOV $89.45
- ELVN $15.81
- Resistance Level
- HOV $97.56
- ELVN $17.54
- Average True Range (ATR)
- HOV 6.17
- ELVN 1.30
- MACD
- HOV -1.39
- ELVN -0.04
- Stochastic Oscillator
- HOV 12.78
- ELVN 38.06
About HOV Hovnanian Enterprises Inc.
Hovnanian Enterprises Inc conducts all of its homebuilding and financial services operations . The company designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes in planned residential developments. It has two distinct operations: homebuilding and financial services. Its homebuilding operations are divided geographically into three segments; Northeast which includes Delaware, Maryland, New Jersey, Ohio, Pennsylvania, Virginia and West Virginia; Southeast which includes Florida, Georgia and South Carolina; and West which includes Arizona, California and Texas. The firm generates maximum revenue from West Segment.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.